跳至主要内容
临床试验/NL-OMON56710
NL-OMON56710
尚未招募
不适用

The value of combined Quantitative MRI for Treatment Response Assessment in head and neck cancer patients receiving (Chemo)radiotherapy. - QTRAC

Amsterdam UMC0 个研究点目标入组 30 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
Amsterdam UMC
入组人数
30
状态
尚未招募
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Observational non invasive

研究者

发起方
Amsterdam UMC

入排标准

入选标准

  • 1\) Newly diagnosed tumours classified as stage T2\-4 N0\-2 located in the larynx,
  • oropharynx or hypopharynx
  • (unknown primary and oral cavity are not eligible)
  • 2\) Histopathological diagnosis of invasive squamous cell carcinoma in the
  • primary tumour
  • 3\) (Chemo)Radiotherapy planned to start within 6 weeks from baseline imaging of
  • tumour assessment
  • 4\) No distant metastasis (M0\)
  • 5\) WHO performance status 0\-2
  • 6\) \>\= 18 years of age

排除标准

  • Each of the following criteria will result in exclusion from participation in
  • this study:
  • 1\) Age \< 18 years
  • 2\) Pregnancy
  • 3\) Patients carrying a pacemaker, or unable to undergo an MRI on a 3T MRI
  • 4\) Primary tumour of the oral cavity or unknown primary tumour
  • 5\) Prior or current anticancer treatment to the head and neck area (e.g.
  • radical attempted or tumour
  • reductive surgery, neo\-adjuvant or concomitant chemotherapy, EGFR inhibitors or
  • radiotherapy),

结局指标

主要结局

未指定

相似试验